109 related articles for article (PubMed ID: 22151005)
61. Hypopituitarism and anemia: effect of replacement therapy with hydrocortisone and/or levothyroxine.
Nishioka H; Haraoka J
J Endocrinol Invest; 2005 Jun; 28(6):528-33. PubMed ID: 16117194
[TBL] [Abstract][Full Text] [Related]
62. Metabolic Syndrome in Hypopituitarism.
Miljić D; Popovic V
Front Horm Res; 2018; 49():1-19. PubMed ID: 29895033
[TBL] [Abstract][Full Text] [Related]
63. Evaluation of different hydrocortisone treatment strategies in transsphenoidal pituitary surgery.
Fridman-Bengtsson O; Höybye C; Porthén L; Stjärne P; Hulting AL; Sunnergren O
Acta Neurochir (Wien); 2019 Aug; 161(8):1715-1721. PubMed ID: 31065892
[TBL] [Abstract][Full Text] [Related]
64. [Multifocal osteonecrosis in long-term corticoid treatment secondary to panhypopituitarism: a case report].
Ibáñez D; Martín MD; Rubio RÁ; Muel C
Endocrinol Nutr; 2013; 60(7):416-8. PubMed ID: 23108054
[No Abstract] [Full Text] [Related]
65. Hypopituitarism in the elderly in the presence of elevated thyroid stimulating hormone levels.
Beringer T; McClements B; Weir I; Gilmore D; Kennedy L
Postgrad Med J; 1988 Dec; 64(758):943-4. PubMed ID: 3256811
[TBL] [Abstract][Full Text] [Related]
66. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism.
Barbetta L; Dall'Asta C; Re T; Libè R; Costa E; Ambrosi B
J Endocrinol Invest; 2005; 28(7):632-7. PubMed ID: 16218046
[TBL] [Abstract][Full Text] [Related]
67. Mortality in patients with pituitary disease.
Sherlock M; Ayuk J; Tomlinson JW; Toogood AA; Aragon-Alonso A; Sheppard MC; Bates AS; Stewart PM
Endocr Rev; 2010 Jun; 31(3):301-42. PubMed ID: 20086217
[TBL] [Abstract][Full Text] [Related]
68. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors.
van Zaane B; Nur E; Squizzato A; Gerdes VE; Büller HR; Dekkers OM; Brandjes DP
J Thromb Haemost; 2010 Nov; 8(11):2483-93. PubMed ID: 20735729
[TBL] [Abstract][Full Text] [Related]
69. The effect of hypopituitarism on life expectancy.
Bates AS; Van't Hoff W; Jones PJ; Clayton RN
J Clin Endocrinol Metab; 1996 Mar; 81(3):1169-72. PubMed ID: 8772595
[TBL] [Abstract][Full Text] [Related]
70. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens.
Bleicken B; Hahner S; Loeffler M; Ventz M; Allolio B; Quinkler M
Eur J Endocrinol; 2008 Dec; 159(6):811-7. PubMed ID: 18819943
[TBL] [Abstract][Full Text] [Related]
71. Editorial: glucocorticoid replacement--how much is enough?
Lukert BP
J Clin Endocrinol Metab; 2006 Mar; 91(3):793-4. PubMed ID: 16522704
[No Abstract] [Full Text] [Related]
72. Recent Advances in Hydrocortisone Replacement Treatment.
Mallappa A; Debono M
Endocr Dev; 2016; 30():42-53. PubMed ID: 26683495
[TBL] [Abstract][Full Text] [Related]
73. Tea drinking and haemostasis: a randomized, placebo-controlled, crossover study in free-living subjects.
Vorster H; Jerling J; Oosthuizen W; Cummings J; Bingham S; Magee L; Mulligan A; Runswick S
Haemostasis; 1996; 26(1):58-64. PubMed ID: 8698279
[TBL] [Abstract][Full Text] [Related]
74. Optimal glucocorticoid replacement therapy.
Katz J; DeVile CJ; Stanhope R
Clin Endocrinol (Oxf); 1997 Aug; 47(2):251. PubMed ID: 9302403
[No Abstract] [Full Text] [Related]
75. Twice-weekly regimen for replacement therapy in uncooperative patient with hypopituitarism.
Nathan AW; Rose GL; Barkley AS; McDevitt M
Lancet; 1979 Feb; 1(8111):319. PubMed ID: 84966
[No Abstract] [Full Text] [Related]
76. Blood fibrinolytic activity during major surgery in unsupplemented glucocorticoid-treated patients.
Engquist A
Br J Anaesth; 1976 Aug; 48(8):805-8. PubMed ID: 947347
[TBL] [Abstract][Full Text] [Related]
77. Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma.
Hammarstrand C; Ragnarsson O; Hallén T; Andersson E; Skoglund T; Nilsson AG; Johannsson G; Olsson DS
Eur J Endocrinol; 2017 Sep; 177(3):251-256. PubMed ID: 28596421
[TBL] [Abstract][Full Text] [Related]
78. Shorter telomeres associated with high doses of glucocorticoids: the link to increased mortality?
Athanasoulia-Kaspar AP; Auer MK; Stalla GK; Jakovcevski M
Endocr Connect; 2018 Aug; 7(11):1217-26. PubMed ID: 30352410
[TBL] [Abstract][Full Text] [Related]
79. Bone safety of dual-release hydrocortisone in patients with hypopituitarism.
Frara S; Chiloiro S; Porcelli T; Giampietro A; Mazziotti G; De Marinis L; Giustina A
Endocrine; 2018 Jun; 60(3):528-531. PubMed ID: 29313195
[No Abstract] [Full Text] [Related]
80. Is vascular mortality increased in hypopituitarism?
Erfurth EM; Bülow B; Hagmar LE
Pituitary; 2000 Oct; 3(2):77-81. PubMed ID: 11141699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
